• Explore /
  • Poster
  • / Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma (RCC): Updated results from phase I/Ib IVY study.

Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma (RCC): Updated results from phase I/Ib IVY study.

Abstract Poster

Authors

null

Aung Naing

University of Texas MD Anderson Cancer Center, Houston, TX

Aung Naing , Kyriakos P. Papadopoulos , Deborah J.L. Wong , Raid Aljumaily , Annie Hung , Manuel Afable , Jong Seok Kim , David Ferry , Alexandra Drakaki , Johanna C. Bendell , Nizar M. Tannir

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02009449

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 679)

Abstract #

679

Poster Bd #

F21

Abstract Disclosures

Similar Posters

First Author: Meredith M. Regan

First Author: Xiting Cao

First Author: Giacomo Nuvola

First Author: Marc-Oliver Grimm